The HIV prevention landscape is evolving rapidly, and future efficacy trials of candidate vaccines, which remain the best long-term option for stemming the HIV epidemic, will be conducted in the context of partially effective nonvaccine prevention modalities. It is essential that these trials provide for valid and efficient evaluation of vaccine efficacy and immune correlates. The availability of partially effective prevention modalities presents opportunities to study their interactions with vaccines to maximally reduce HIV incidence. This article proposes an approach for conducting future vaccine efficacy trials in the context of background use of partially effective nonvaccine prevention modalities, and for conducting future vaccine efficacy trials that provide nonvaccine prevention modalities in one or more of the randomized study groups. Strategies are discussed for responding to emerging evidence on nonvaccine prevention modalities during ongoing vaccine trials. Next-generation HIV vaccine efficacy trials will almost certainly be more complex in their design and implementation but may become more relevant to at-risk populations and better suited to the ultimate goal of reducing HIV incidence at the population level.
Get full access to this article
View all access options for this article.
References
1.
Abdool KarimQ, Abdool KarimSS, FrohlichJAet al.Effectiveness and safety of tenofovir gel, an antiretroviral microbicide, for the prevention of HIV infection in women. Science, 2010; 329,5996:1168–1174Epub 2010/07/2110.1126/science.1193748PubMed20643915PubMed CentralPMC3001187.
2.
GrantRM, LamaJR, AndersonPLet al.Preexposure chemoprophylaxis for HIV prevention in men who have sex with men. N Engl J Med, 2010; 363,27:2587–2599Epub 2010/11/2610.1056/NEJMoa1011205PubMed21091279PubMed CentralPMC3079639.
3.
BaetenJM, DonnellD, NdasePet al.Antiretroviral prophylaxis for HIV prevention in heterosexual men and women. N Engl J Med, 2012; 367,5:399–410Epub 2012/07/1310.1056/NEJMoa1108524PubMed22784037.
4.
ThigpenMC, KebaabetswePM, PaxtonLAet al.Antiretroviral preexposure prophylaxis for heterosexual HIV transmission in Botswana. N Engl J Med, 2012; 367,5:423–434Epub 2012/07/1310.1056/NEJMoa1110711PubMed22784038.
5.
Van DammeL, CorneliA, AhmedKet al.Preexposure prophylaxis for HIV infection among African women. N Engl J Med, 2012; 367,5:411–422. 10.1056/NEJMoa1202614.
6.
CelumC, BaetenJM. Tenofovir-based pre-exposure prophylaxis for HIV prevention: Evolving evidence. Curr Opin Infect Dis, 2012; 25,1:51–57Epub 2011/12/1410.1097/QCO.0b013e32834ef5efPubMed22156901PubMed CentralPMC3266126.
7.
National Institute of Allergy and Infectious Diseases (NIAID). National Institutes of Health: NIH modifies ‘VOICE’ HIV prevention study in women. 2011.
8.
National Institute of Allergy and Infectious Diseases (NIAID). National Institutes of Health: NIH discontinues Tenofovir gel in “VOICE” HIV prevention study. 2011.
9.
CohenMS, MuessigKE, SmithMK, PowersKA, KashubaAD. Antiviral agents and HIV prevention: Controversies, conflicts, and consensus. AIDS, 2012; 26,13:1585–1598Epub 2012/04/1810.1097/QAD.0b013e3283543e83PubMed22507927.
10.
MarrazzoJ, RamjeeG, NairG, PalaneeT, MkhizeB, NakabiitoC, TaljaardM, PiperJ, Gomez-FelicianoK, ChirenjeM. the VOICE Study Team. Pre-exposure Prophylaxis for HIV in Women: Daily Oral Tenofovir, Oral Tenofovir/Emtricitabine, or Vaginal Tenofovir Gel in the VOICE Study (MTN 003)Conference on Retroviruses and Opportunistic Infections, Atlanta, Georgia, 2013.
11.
CohenMS, ChenYQ, McCauleyMet al.Prevention of HIV-1 infection with early antiretroviral therapy. N Engl J Med, 2011; 365,6:493–505Epub 2011/07/2010.1056/NEJMoa1105243PubMed21767103PubMed CentralPMC3200068.
12.
AIDS Vaccine Advocacy Coalition (AVAC). 2012. Ongoing and planned microbicide clinical trials. www.avac.org/ht/a/GetDocumentAction/i/3109.
13.
Rerks-NgarmS, PitisuttithumP, NitayaphanSet al.Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand. N Engl J Med, 2009; 361,23:2209–2220Epub 2009/10/2210.1056/NEJMoa0908492PubMed19843557.
14.
National Institute of Allergy and Infectious Diseases (NIAID). National Institutes of Health: NIH discontinues immunizations in HIV vaccine study. 2013.
15.
GilbertPB, GroveD, GabrielEet al.A sequential phase 2b trial design for evaluating vaccine efficacy and immune correlates for multiple HIV vaccine regimens. Stat Commun Infect Dis, 2011; 3,1Epub 2012/11/2823181167PubMed CentralPMC3502884.
16.
ExclerJL, RidaW, PriddyF, GilmousJ, Mc DermottAB, KamaliA, AnzalaO, MutuaG, SandersEJ, KoffW, BerkleyS. AIDS vaccines and pre-exposure prophylaxis: Is synergy possible?AIDS Res Human Retroviruses, 2011; 27,6:669–680PubMed3101085.
17.
QinL, GilbertPB, CoreyL, McElrathMJ, SelfSG. A framework for assessing immunological correlates of protection in vaccine trials. J Infect Dis, 2007; 196:1304–1312.
18.
Clements-MannML. Lessons for AIDS vaccine development from non-AIDS vaccines. AIDS Res Hum Retroviruses, 1998; 14,Suppl 3:S197–203Epub 1998/11/14PubMed9814944.
19.
FauciAS. The AIDS epidemic—considerations for the 21st century. N Engl J Med, 1999; 341,14:1046–1050Epub 1999/09/3010.1056/NEJM199909303411406PubMed10502595.
PlotkinSA, GilbertPB. Nomenclature for immune correlates of protection after vaccination. Clin Infect Dis, 2012; 54,11:1615–1617Epub 2012/03/2310.1093/cid/cis238PubMed22437237PubMed CentralPMC3348952.
22.
NelA, KamupiraM, WoodsongC, MontgomeryE, NuttallJ. Safety, Acceptability, Pharmacokinetic Assessment (Adherence) of Monthly Dapivirine Vaginal Microbicide Rings (Ring-004) for HIV Prevention. 19th Conference on Retroviruses and Opportunistic Infections, March 5–8, 2012, Seattle, WA.
23.
KurthAE, CelumC, BaetenJM, VermundSH, WasserheitJN. Combination HIV prevention: Significance, challenges, and opportunities. Curr HIV/AIDS Rep, 2011; 8,1:62–72Epub 2010/10/1410.1007/s11904-010-0063-3PubMed20941553PubMed CentralPMC3036787.
24.
CranageM, SharpeS, HerreraCet al.Prevention of SIV rectal transmission and priming of T cell responses in macaques after local pre-exposure application of tenofovir gel. PLoS Med, 2008; 5,8:e157discussion e. Epub 2008/08/0810.1371/journal.pmed.0050157PubMed18684007PubMed CentralPMC2494562.
SchaperC, FlemingTR, SelfSG, RidaWN. Statistical issues in the design of HIV vaccine trials. Annu Rev Public Health, 1995; 16:1–22Epub 1995/01/0110.1146/annurev.pu.16.050195.000245PubMed7639865.
27.
Hogben MaNL. Disinhibition and risk compensation: Scope, definitions, and perspective. Sexually Transmit Dis, 2008; 35,12:1009–1010.
28.
Eaton LAaSCK. Risk compensation in HIV prevention: Implications for vaccines, microbicides, and other biomedical HIV prevention technologies. Curr HIV/AIDS Rep, 2007; 4,4:165–172.
29.
SelfSG, PrenticeRL. Asymptotic distribution theory and efficiency results for case-cohort studies. Ann Stat, 1988; 16,1:64–81. 10.2307/2241423.
30.
BarlowWE. Robust variance estimation for the case-cohort design. Biometrics, 1994; 50,4:1064–1072Epub 1994/12/01PubMed7786988.
31.
ChenK, LoS-H. Case-cohort and case-control analysis with Cox's model. Biometrika, 1999; 86,4:755–764. 10.1093/biomet/86.4.755.
ChenK. Generalized case-cohort sampling. J R Stat Soc Ser B, 2001; 63,4:791–809. 10.2307/2680667.
34.
KulichM, LinDY. Improving the efficiency of relative-risk estimation in case-cohort studies. J Am Stat Assoc, 2004; 99:832–844.
35.
LiZ, GilbertP, NanB. Weighted likelihood method for grouped survival data in case-cohort studies with application to HIV vaccine trials. Biometrics, 2008; 64,4:1247–1255Epub 2008/11/2710.1111/j.1541-0420.2008.00998.xPubMed19032178.
36.
PrenticeRL. A case-cohort design for epidemiologic cohort studies and disease prevention trials. Biometrika, 1986; 73,1:1–11. 10.1093/biomet/73.1.1.
37.
PiegorschWW, WeinbergCR, TaylorJA. Non-hierarchical logistic models and case-only designs for assessing susceptibility in population-based case-control studies. Stat Med, 1994; 13,2:153–162Epub 1994/01/30PubMed8122051.
38.
UmbachDM, WeinbergCR. Designing and analysing case-control studies to exploit independence of genotype and exposure. Stat Med, 1997; 16,15:1731–1743Epub 1997/08/15PubMed9265696.
39.
VittinghoffE, BauerDC. Case-only analysis of treatment-covariate interactions in clinical trials. Biometrics, 2006; 62,3:769–776Epub 2006/09/2110.1111/j.1541-0420.2006.00511.xPubMed16984319.
40.
ZhangM, GilbertPB. Increasing the efficiency of prevention trials by incorporating baseline covariates. Stat Commun Infect Dis, 2010; 2,1Epub 2010/12/1510.2202/1948-4690.1002PubMed21152074PubMed CentralPMC2997740.
41.
DaiJ, GilbertPB, HughesJP, BrownE. Estimating PrEP efficacy for HIV prevention among participants with a threshold level of drug concentration. Am J Epidemiol, 2013; 177:256–263.
42.
RidaW, FastP, HoffR, FlemingT. Intermediate-size trials for the evaluation of an HIV vaccine candidate: A workshop summary. J Acquir Immune Defic Syndr Hum Retrovirol, 1997; 16:195–203.
43.
DemetsDL. Current development in clinical trials: Issues old and new. Stat Med, 2012; 31,25:2944–2954Epub 2012/06/2810.1002/sim.5405PubMed22736410.
44.
FlemingTR. Current issues in non-inferiority trials. Stat Med, 2008; 27,3:317–332Epub 2007/03/0710.1002/sim.2855PubMed17340597.
45.
FlemingTR, Odem-DavisK, RothmannMD, Li ShenY. Some essential considerations in the design and conduct of non-inferiority trials. Clin Trials, 2011; 8,4:432–439Epub 2011/08/1310.1177/1740774511410994PubMed21835862PubMed CentralPMC3312046.
46.
CooperCJ, MetchB, DragavonJet al.Vaccine-induced HIV seropositivity/reactivity in noninfected HIV vaccine recipients. JAMA, 2010; 304,3:275–283Epub 2010/07/2010.1001/jama.2010.926PubMed20639561PubMed CentralPMC3086635.
47.
Gilead Sciences I: U.S. Food and Drug Administration Approves Gilead 's Truvada® for Reducing the Risk of Acquiring HIV Business Wire. July16, 2012.
48.
Services DoHaH: Antiretroviral agents in HIV-1-infected adults and adolescents. http://www.aidsinfo.nih.gov/contentfiles/lvguidelines/adultandadolescentgl.pdf
49.
PattersonK, PrinceH, KraftEet al.Exposure of Extracellular and Intracellular Tenofovir and Emtricitabine in Mucosal Tissues after a Single Dose of Fixed-Dose TDF/FTC: Implications for Pre-exposure HIV Prophylaxis. XVIII International AIDS Conference, July 18–23, 2010, Vienna, Austria.
50.
FullerWA. Measurement Error Models. John Wiley and Sons: New York, 1987.
51.
WangCY, HuangY, ChaoEC, JeffcoatMK. Expected estimating equations for missing data, measurement error, and misclassification, with application to longitudinal nonignorable missing data. Biometrics, 2008; 64,1:85–95Epub 2007/07/0510.1111/j.1541-0420.2007.00839.xPubMed17608787.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
